Revenue Recognition and Accounts Receivable Revenue Disaggregation (Table) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Disaggregation of Revenue [Line Items]
Net sales	$ 3,243.2	$ 3,653.5
Brands
Disaggregation of Revenue [Line Items]
Net sales	2,116.9	2,309.1
Generics
Disaggregation of Revenue [Line Items]
Net sales	1,126.3	1,344.4
Lipitor
Disaggregation of Revenue [Line Items]
Net sales	388.0	388.9
Norvasc
Disaggregation of Revenue [Line Items]
Net sales	172.3	176.3
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	112.6	114.2
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	96.7	80.2
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	98.5	100.7
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	82.4	75.0
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	63.4	72.2
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	59.3	59.4
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	60.2	58.0
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	37.1	42.5
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	58.3	55.2
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	42.8	48.2
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	32.3	34.5
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	33.3	33.0
Developed Markets Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	1,019.8	1,178.8
Developed Markets Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	871.9	986.6
Greater China \| Brands
Disaggregation of Revenue [Line Items]
Net sales	552.8	541.8
Greater China \| Generics
Disaggregation of Revenue [Line Items]
Net sales	2.7	2.1
Japan, Australia and New Zealand Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	141.8	184.1
Japan, Australia and New Zealand Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	134.3	133.7
Emerging Markets Segment \| Brands
Disaggregation of Revenue [Line Items]
Net sales	402.5	404.4
Emerging Markets Segment \| Generics
Disaggregation of Revenue [Line Items]
Net sales	117.4	222.0
Operating Segment \| Developed Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	1,891.7	2,165.4
Operating Segment \| Greater China
Disaggregation of Revenue [Line Items]
Net sales	555.5	543.9
Operating Segment \| Japan, Australia and New Zealand Segment
Disaggregation of Revenue [Line Items]
Net sales	276.1	317.8
Operating Segment \| Emerging Markets Segment
Disaggregation of Revenue [Line Items]
Net sales	$ 519.9	$ 626.4